Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries

ABSTRACTThe plaque reduction neutralization test (PRNT) is used widely to measure the neutralization activity of anti-dengue virus (DENV) antibodies, but it is time-consuming and labor-intensive and has low sample throughput. For fast and convenient measurement of neutralizing antibodies, especially in evaluating the efficiency of the DENV vaccines on a large scale, a new method is needed to replace PRNT. In recent decades, several microneutralization assays have been developed to overcome the limitations of PRNT. In the present study, we evaluated one of these, the enzyme-linked immunospot microneutralization test (ELISPOT-MNT), in comparison with PRNT. ELISPOT-MNT is performed in 96-well format, and the plaques are developed after 2 to 4 days using an ELISA to transform them into spots, which are detected automatically with an ELISPOT instrument. The assay is faster than PRNT, has a high throughput, and is more objective. We used 10 monoclonal antibodies (MAbs) against domain III of the DENV envelope protein (EDIII) to evaluate the two assays; all of these MAbs cross-react with all four serotypes of DENV as measured by immunofluorescence assay. The two neutralization assays were performed simultaneously to measure the 50% inhibitory concentration (IC50) of these MAbs. Using PRNT as the reference and treating IC50values higher than 50 μg/ml of MAbs as negative, ELISPOT-MNT showed a sensitivity of 95.6% and specificity of 88.24% when 10 MAbs were tested against four DENV serotype strains. A good correlation (R2= 0.672;P= 0.000) was observed between the two assays, making ELISPOT-MNT a potentially valuable method for measure of neutralizing antibodies against DENV.

Download Full-text

Phage display demonstrates durable differences in serological profile by route of inoculation in primary infections of non-human primates with Dengue Virus 1

Scientific Reports ◽

10.1038/s41598-021-90318-z ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Jayant V. Rajan ◽

Michael McCracken ◽

Caleigh Mandel-Brehm ◽

Greg Gromowski ◽

Simon Pollett ◽

...

Keyword(s):

Dengue Virus ◽

Phage Display ◽

Denv Infection ◽

Phage Library ◽

Humoral Immune ◽

Linear Peptide ◽

Humoral Immune Responses ◽

High Resolution Map ◽

Domain Iii ◽

Inoculation Route

AbstractNatural dengue virus (DENV) infections occur by mosquito bite but how the inoculation route affects the humoral immune response is unknown. We serologically profiled 20 non-human primates (NHP) from a prior study of DENV1 infection where animals were inoculated by mosquito (N = 10) or subcutaneous injection (N = 10). Using a comprehensive, densely tiled and highly redundant pan-flavivirus programmable phage library containing 91,562 overlapping 62 amino acid peptides, we produced a high-resolution map of linear peptide sequences enriched during DENV seroconversion. Profiles in mosquito-inoculated and subcutaneously-inoculated animals were similar up to 90 days after primary infection, but diverged at 1 year with differences in sero-reactivity in the Envelope (E; residues 215–406; p < 0.08), and Nonstructural-3 (NS3; residues 549–615; p < 0.05) proteins in mosquito-inoculated versus subcutaneously-inoculated animals. Within the E protein, residues 339–384 in domain III accounted for > 99% of the observed sero-reactivity difference. Antibody breadth did not vary by mode of inoculation. The differential reactivity to E domain III seen by phage display validated orthogonally by ELISA, but did not correlate with late neutralization titers. Serological profiling of humoral immune responses to DENV infection in NHP by programmable phage display demonstrated durable differences in sero-reactivity by route of inoculation.

Download Full-text

Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora’s box?

BMC Infectious Diseases ◽

10.1186/s12879-018-3572-0 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Shannon A. Gunawardana ◽

Robert H. Shaw

Keyword(s):

Monoclonal Antibodies ◽

Dengue Virus ◽

Zika Virus ◽

Envelope Protein ◽

Virus Envelope ◽

Virus Envelope Protein

Download Full-text

Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding

Journal of General Virology ◽

10.1099/vir.0.037317-0 ◽

2012 ◽

Vol 93 (1) ◽

pp. 72-82 ◽

Cited By ~ 61

Author(s):

Daniel Watterson ◽

Bostjan Kobe ◽

Paul R. Young

Keyword(s):

Cell Surface ◽

Dengue Virus ◽

Site Directed Mutagenesis ◽

Cell Surface Receptor ◽

Protein Fusion ◽

Virus Envelope ◽

Putative Receptor ◽

E Protein ◽

Surface Receptor ◽

Domain Iii

The dengue virus (DENV) envelope (E) protein mediates virus entry into cells via interaction with a range of cell-surface receptor molecules. Cell-surface glycosaminoglycans (GAGs) have been shown to play an early role in this interaction, and charged oligosaccharides such as heparin bind to the E protein. We have examined this interaction using site-directed mutagenesis of a recombinant form of the putative receptor-binding domain III of the DENV-2E protein expressed as an MBP (maltose-binding protein)-fusion protein. Using an ELISA-based GAG-binding assay, cell-based binding analysis and antiviral-activity assays, we have identified two critical residues, K291 and K295, that are involved in GAG interactions. These studies have also demonstrated differential binding between mosquito and human cells.

Download Full-text

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines

Vaccines ◽

10.3390/vaccines8020307 ◽

2020 ◽

Vol 8 (2) ◽

pp. 307 ◽

Cited By ~ 3

Author(s):

César López-Camacho ◽

Giuditta De Lorenzo ◽

Jose Luis Slon-Campos ◽

Stuart Dowall ◽

Peter Abbink ◽

...

Keyword(s):

Immune Responses ◽

Dengue Virus ◽

Zika Virus ◽

Neutralizing Antibodies ◽

Vaccine Candidate ◽

Protein Domain ◽

Virus Envelope ◽

Zikv Infection ◽

Domain Iii ◽

Open Question

The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable vaccine candidate for the correct induction of protective immune responses against ZIKV.

Download Full-text